60 Degrees Pharmaceuticals (NASDAQ:SXTP) CEO Buys $10,143.00 in Stock

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) CEO Geoffrey Dow acquired 7,350 shares of 60 Degrees Pharmaceuticals stock in a transaction on Friday, June 12th. The stock was acquired at an average cost of $1.38 per share, for a total transaction of $10,143.00. Following the purchase, the chief executive officer owned 24,131 shares of the company’s stock, valued at approximately $33,300.78. This represents a 43.80% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

60 Degrees Pharmaceuticals Stock Performance

60 Degrees Pharmaceuticals stock traded up $0.13 on Monday, reaching $1.49. The company’s stock had a trading volume of 85,627 shares, compared to its average volume of 2,528,288. The company has a market cap of $3.96 million, a price-to-earnings ratio of -0.17 and a beta of 2.65. The business’s fifty day moving average price is $1.60 and its 200 day moving average price is $2.51. 60 Degrees Pharmaceuticals Inc. has a twelve month low of $1.22 and a twelve month high of $10.77.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.52). The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.44 million. As a group, equities analysts forecast that 60 Degrees Pharmaceuticals Inc. will post -3.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. HC Wainwright lowered 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 20th. Wall Street Zen lowered 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, March 27th. Finally, Ascendiant Capital Markets cut their price target on 60 Degrees Pharmaceuticals from $4.20 to $3.70 and set a “buy” rating on the stock in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, 60 Degrees Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $13.85.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.